A PROSPECTIVE MULTICENTER RANDOMIZED STUDY COMPARING STRONTIUM-89 CHLORIDE AND PALLIATIVE LOCAL FIELD RADIOTHERAPY IN PATIENTS WITH HORMONAL ESCAPED ADVANCED PROSTATIC CANCER
OBJECTIVES: I. Compare, in a randomized Phase III setting, the subjective response rate,
time to progression, and survival of patients with hormone-refractory prostate cancer with
painful osseous metastases treated with either strontium-89 or palliative local
radiotherapy. II. Compare the quality of life achieved on these two regimens. III. Determine
the toxicity and morbidity of treatment on these two regimens. IV. Compare the cost
effectiveness of these two regimens.
OUTLINE: Randomized study. Arm I: Radioisotope therapy. Strontium-89 chloride, Strontium-89.
Arm II: Radiotherapy. Involved-field irradiation (equipment unspecified).
PROJECTED ACCRUAL: 200 patients will be entered over 2 years.
Primary Purpose: Treatment
G. O. N. Oosterhof, MD, PhD
Academisch Ziekenhuis Maastricht
United States: Federal Government